/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

EYEPOINT PHARMACEUTICALS INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$14.25 0.0606(6.06%) EYPT at 04 Dec 2025 04:31 PM Biotechnology
Lowest Today 14.03
Highest Today 14.59
Today’s Open 14.09
Prev. Close 13.69
52 Week High 14.96
52 Week Low 3.91
Day’s Range: Low 14.03 High 14.59
52-Week Range: Low 3.91 High 14.96
1 day return -
1 Week return -2.12
1 month return +17.32
3 month return +22.05
6 month return +77.35
1 year return +70.98
3 year return +336.18
5 year return +179.32
10 year return -

Institutional Holdings

Cormorant Asset Management, LLC 12.08

Suvretta Capital Management, LLC 9.87

Adage Capital Partners Gp LLC 9.87

BlackRock Inc 7.78

Federated Hermes Inc 6.67

Franklin Resources Inc 6.24

Vanguard Group Inc 5.52

TCG Crossover Management, LLC 5.18

Citadel Advisors Llc 3.40

Federated Hermes Kaufmann Growth 2.96

Federated Hermes Kaufmann R 2.96

Vanguard Total Stock Mkt Idx Inv 2.94

Franklin Biotechnology Discv A(acc)USD 2.77

Geode Capital Management, LLC 2.31

State Street Corp 2.20

iShares Russell 2000 ETF 2.16

Federated Hermes Kaufmann Small Cap A 2.15

Federated Hermes Kaufmann Small Cap Grow 2.15

Patient Square Capital 1.96

Goldman Sachs Group Inc 1.86

Franklin US Small Cap Growth Equity 1.84

Franklin Small Cap Growth Adv 1.70

Essex Woodlands Health Ventures 1.70

5AM Venture Management, LLC 1.52

Franklin Biotechnology Discovery A 1.51

Aberdeen Group PLC 1.50

Bank of America Corp 1.18

Morgan Stanley - Brokerage Accounts 1.14

Vanguard Institutional Extnd Mkt Idx Tr 1.07

abrdn Healthcare Investors 0.98

HSBC Holdings PLC 0.92

Fidelity Small Cap Index 0.90

Federated Hermes MDT SCC Institutional 0.90

Federated Hermes MDT Small Cap Core IS 0.90

HSBC GIF Glb Eq Sust Hlthcare AC USD 0.87

Nantahala Capital Management, LLC 0.86

Allspring (Lux) WW Glb L/SEq IPUSD Acc 0.83

iShares Russell 2000 Value ETF 0.80

HBM Healthcare Investments AG Ord 0.73

Fidelity Extended Market Index 0.54

Market Status

Strong Buy: 9

Buy: 4

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 1133.36 M

PB Ratio 5.8974

PE Ratio 0.0

Enterprise Value 997.82 M

Total Assets 418.47 M

Volume 810494

Company Financials

Annual Revenue FY23:42523000 42.5M, FY22:41404000 41.4M, FY21:36939000 36.9M, FY20:34437000 34.4M, FY19:20365000 20.4M

Annual Profit FY23:35479000 35.5M, FY22:33078000 33.1M, FY21:28762000 28.8M, FY20:28613000 28.6M, FY19:17678000 17.7M

Annual Net worth FY23:-100148000 -100.1M, FY22:-124512000 -124.5M, FY21:-63915000 -63.9M, FY20:-52651000 -52.7M, FY19:-62969000 -63.0M

Quarterly Revenue Q3/2025:966000 1.0M, Q2/2025:5333000 5.3M, Q1/2025:24453000 24.5M, Q3/2024:10524000 10.5M, Q2/2024:9477000 9.5M

Quarterly Profit Q3/2025:245000 0.2M, Q2/2025:5168000 5.2M, Q1/2025:23648000 23.6M, Q3/2024:9788000 9.8M, Q2/2024:8076000 8.1M

Quarterly Net worth Q3/2025:-59732000 -59.7M, Q2/2025:-59426000 -59.4M, Q1/2025:-45195000 -45.2M, Q3/2024:-29361000 -29.4M, Q2/2024:-30826000 -30.8M

Fund house & investment objective

Company Information EyePoint Pharmaceuticals, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Organisation Biotechnology

Employees 165

Industry Biotechnology

CEO Dr. Jay S. Duker M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow